A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Eastern Cooperative Oncology Group
Massachusetts General Hospital
Hoffmann-La Roche
National Cancer Institute (NCI)
Chang Gung Memorial Hospital
M.D. Anderson Cancer Center
Icahn School of Medicine at Mount Sinai
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Providence Health & Services
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sun Yat-sen University
Revolution Medicines, Inc.
Pfizer
Seagen Inc.
Peking University People's Hospital
H. Lee Moffitt Cancer Center and Research Institute
University of Colorado, Denver
Jules Bordet Institute